Lumena's rare liver disease candidate wins orphan status from FDA

09/30/2013 | Pharmaceutical Business Review Online

Lumena Pharmaceuticals' experimental drug LUM001 secured orphan-drug designation from the FDA as a treatment for Alagille syndrome, primary sclerosing cholangitis, progressive familial intrahepatic cholestasis and primary biliary cirrhosis. The drug is in a midstage pediatric trial for Alagille syndrome.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC